Procter & Gamble Health Ltd

Procter & Gamble Health announced that the Board of Directors of the Company at its meeting held on 29 May 2025, inter alia, have recommended the final dividend of Rs 45 per equity Share (i.e. 450%) , subject to the approval of the shareholders.Powered by Capital Market - Live

Net profit of Procter & Gamble Health rose 31.40% to Rs 61.18 crore in the quarter ended March 2025 as against Rs 46.56 crore during the previous quarter ended March 2024. Sales rose 23.17% to Rs 310.99 crore in the quarter ended March 2025 as against Rs 252.48 crore during the previous quarter ended March 2024. ParticularsQuarter EndedMar. 2025Mar. 2024% Var. Sales310.99252.48 23 OPM %26.0226.71 - PBDT83.9069.56 21 PBT78.5362.72 25 NP61.1846.56 31 Powered by Capital Market - Live

Procter & Gamble Health will hold a meeting of the Board of Directors of the Company on 29 May 2025.Powered by Capital Market - Live

Net profit of Procter & Gamble Health rose 26.13% to Rs 90.90 crore in the quarter ended December 2024 as against Rs 72.07 crore during the previous quarter ended December 2023. Sales declined 0.06% to Rs 309.77 crore in the quarter ended December 2024 as against Rs 309.97 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales309.77309.97 0 OPM %39.8532.79 - PBDT127.24106.64 19 PBT121.6999.72 22 NP90.9072.07 26 Powered by Capital Market - Live

Procter & Gamble Health announced that the Board of Directors of the Company at its meeting held on 12 February 2025, inter alia, have recommended the interim dividend of Rs 80 per equity Share (i.e. 800%) , subject to the approval of the shareholders.Powered by Capital Market - Live

The company's revenue from operations remained flat to Rs 309.77 crore in Q3 FY25, compared to the same quarter of the previous year. Total expenses were at Rs 192.04 crore in Q2 December 2024, down 10.85% on a YoY basis. The cost of materials consumed stood at Rs 61.60 crore (down 10.85% YoY), while employee benefits expenses came in at Rs 61.60 crore (down 13.04% YoY) during the period under review. Milind Thatte, Managing Director, P&G Health India, said, 'This quarter was a period of strategic reinforcement as we took proactive steps to strengthen our supply network. We remain committed to our integrated growth strategy of a focused product portfolio, superiority, productivity, constructive disruption, and an agile and accountable organizational structure. We are confident that this strategy will enable us to meet the evolving needs of our consumers and healthcare professionals alike.' Meanwhile, the board has declared an interim dividend of Rs 80 per equity share for the financial year 2024-25. The record date for the dividend will be 21 February 2025. Procter & Gamble Health (P&G Health) is one of India's largest VMS companies, manufacturing and marketing vitamins, minerals, and supplements products that include Neurobion, Livogen, SevenSeas, Evion, Polybion, and Nasivion. Powered by Capital Market - Live

Procter & Gamble Health will hold a meeting of the Board of Directors of the Company on 12 February 2025.Powered by Capital Market - Live

Profit before tax in Q2 FY25 stood at Rs 111.4 crore, up 26.51% as against Rs 88.05 crore posted in same quarter last year. Total expenses were at Rs 205.29 crore in Q2 September 2024, down 7.91% on YoY basis. Cost of materials consumed stood at Rs 48.17 crore (down 44.82% YoY) while employee benefits expenses came in at Rs 46.22 crore (down 23.77% YoY) during the period under review. Milind Thatte, Managing Director, P superiority (across product, package, brand communication, retail execution, and value), constructive disruption and an agile accountable organization'. He further added, 'We are dedicated to enhancing consumer awareness programs and strengthening our relationships with our customers and stakeholders. We continue to invest in initiatives that address the evolving needs of both consumers and healthcare professionals, along with strengthening our go-to-market model. We have also strengthened our reach, distribution, and retail execution, positioning us for long-term competitiveness'. Procter & Gamble Health (P&G Health) is one of India's largest VMS companies, manufacturing and marketing vitamins, minerals, and supplements products that include Neurobion, Livogen, SevenSeas, Evion, Polybion and Nasivion. The counter has hit a 52-week high at Rs 5,730.75 in today's intra-day session.Powered by Capital Market - Live

Net profit of Procter & Gamble Health rose 25.56% to Rs 82.33 crore in the quarter ended September 2024 as against Rs 65.57 crore during the previous quarter ended September 2023. Sales rose 2.78% to Rs 313.41 crore in the quarter ended September 2024 as against Rs 304.93 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales313.41304.93 3 OPM %36.3929.08 - PBDT117.1794.53 24 PBT111.4088.05 27 NP82.3365.57 26 Powered by Capital Market - Live

Procter & Gamble Health will hold a meeting of the Board of Directors of the Company on 4 November 2024.Powered by Capital Market - Live